The Irish Takeover Panel ‘s is just as strong The December sale of biotech firm Élan to Perrigo brought to an end one of last year's most watched hostile takeover sagas, and has revealed the Irish Takeover Panel's unwavering approach to its rules. The $8.6 billion acquisition by the US pharmaceutical company came off the back of the Irish target's defence of Royalty Pharma's $6.8 billion hostile offer.
